Navigation Links
Anesiva Announces Second Quarter 2008 Financial Results and Update
Date:8/7/2008

several weeks following

treatment.

Additional Development

-- Anesiva out-licensed worldwide rights to its NF-kappa B Decoy program

to Transcription Factor Therapeutics, Inc. Anesiva will receive an

upfront licensing fee, and will be entitled to receive milestone

payments totaling up to $114 million if two products are

commercialized. NF-kappa B is a protein implicated in autoimmune and

inflammatory disease processes, therapeutic areas outside Anesiva's

current focus on pain management.

About Anesiva and its Diverse Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company's first commercial product, Zingo(TM), is available in the U.S. for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. For full Zingo prescribing information and other information, visit http://www.zingo.com. An sNDA is under review at FDA to expand the Zingo label indication to include adults.

The next product in Anesiva's pipeline, Adlea(TM), is currently being evaluated in Phase 3 clinical trials for the management of acute pain following orthopedic surgeries. Adlea has been shown to reduce pain after only a single administration for up to weeks to months in multiple settings based on the results of several mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain.

Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.

Forward-Looking Statements
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
5. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
6. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
7. Anesiva Raises $45 Million in Common Stock Offering
8. Anesiva Announces Completion of Common Stock Offering
9. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
10. Anesiva Appoints Daniel Janney to Board of Directors
11. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... pretty expensive. Now a team led by an engineer ... of designs that will let scientists slash the cost ... pump. , Syringe pumps are used to dispatch precise ... chemicals in a reaction. They can also cost hundreds ... his team of Michigan Tech students published the library ...
(Date:9/18/2014)... device for computing may have just taken an encouraging ... York led by chemist Stephen O,Brien have discovered new ... , Combining both properties is very exciting scientifically for ... the devices that might ultimately be designed, in logic ... single material, however, has proved difficult until now. , ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Whitehouse Laboratories ... with Salem Realty Group and has acquired an additional ... within the Salem Executive Complex adjacent to its current ... held on Friday September 5th. Whitehouse Labs is in ... entire space specifically for package testing. The prime location ...
(Date:9/17/2014)... WA , Sept. 17, 2014 /PRNewswire/ - Oncothyreon ... it intends to offer and sell shares of its ... separate but concurrent underwritten public offerings.  The Series A ... of Oncothyreon Common Stock, provided that conversion will be ... affiliates would beneficially own more than 4.99% of the ...
Breaking Biology Technology:Doing science just got cheaper -- and faster 2Oxides discovered by CCNY team could advance memory devices 2Whitehouse Labs Announces Package Testing Laboratory Expansion 2Whitehouse Labs Announces Package Testing Laboratory Expansion 3Whitehouse Labs Announces Package Testing Laboratory Expansion 4Oncothyreon Announces Proposed Public Offerings 2
... BioLife,s Proprietary, Next Generation, Biopreservation, Media Resulted in Increased Yield ... ... Cells, BOTHELL, Wash., Oct. 24 ... of,proprietary hypothermic storage and cryopreservation media products for,cells, tissues, and organs, ...
... Corp. (Other,OTC: IDTA.PK) released today the Jant Pharmacal ... and Oversees markets., - The strategic partnership ... continues, has resulted in increasing market,penetration over the ... sales,have increased significantly in the United States with ...
... Notice of Allowance of European Patent Application Covering Its Core ... Product Applications Protection Rights to All Cytokine ... ... GenOdyssee (GO), a biotechnology,company dedicated to the discovery and development of ...
Cached Biology Technology:BioLife Solutions HypoThermosol(R) Adopted by MicroIslet for Processing Pancreatic Islet Cells to Treat Diabetes 2BioLife Solutions HypoThermosol(R) Adopted by MicroIslet for Processing Pancreatic Islet Cells to Treat Diabetes 3BioLife Solutions HypoThermosol(R) Adopted by MicroIslet for Processing Pancreatic Islet Cells to Treat Diabetes 4International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees 2International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees 3International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees 4GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution Technology 2GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution Technology 3GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution Technology 4
(Date:9/18/2014)... the ultimate form of camouflage: you don,t just blend ... is not as uncommon as you might think. Kathryn ... explains that the larval life stages of many marine ... the anatomy that most creatures cannot make transparent. Feller ... shield each individual eye unit with an opaque pigment ...
(Date:9/18/2014)... in the protective tentacles of host anemones, but new ... of kilometres across the open ocean. Although the process ... this is the first time that the high level ... , Dr Steve Simpson, Senior Lecturer in Marine Biology ... colleagues from the Australian Research Council Centre of Excellence ...
(Date:9/17/2014)... of the Santa Ana Wildfire Threat Index a ... the powerful, hot, dry Santa Ana wind, which can ... introduced Sept. 17 by the U.S. Forest Service, in ... , The index includes four classification levels ranging from ... fire agencies and other emergency responders, the media and ...
Breaking Biology News(10 mins):Transparent larvae hide opaque eyes behind reflections 2Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2
... (MGH) researchers have developed a new type of miniature ... expand the application of minimally invasive diagnostic and therapeutic ... the team from the Wellman Center for Photomedicine at ... its use in a mouse model. , ...
... 4 cases of botulism following cosmetic injections to the ... unlicensed preparation that resulted in toxin levels up to ... a report in the November 22/29 issue of JAMA. ... by the toxins of the spore-forming bacterium Clostridium botulinum ...
... collaborating institutions report in this week's Science a ... 2.8 kilometers below Earth's surface. Think that's weird? ... water molecules to useable energy. , The ... the three-dimensional shell that encompasses all planetary life. ...
Cached Biology News:Three-dimensional, miniature endoscope opens new diagnostic possibilities 2Highly concentrated botulinum preparation for cosmetic injections can result in severe illness 2Highly concentrated botulinum preparation for cosmetic injections can result in severe illness 3Bacteria that use radiated water as food 2Bacteria that use radiated water as food 3
Mouse Anti-Human Methyl-CpG binding domain protein 2 (MBD2 Monoclonal Antibody Family: Other Applications: Western Blot...
... Shaker combines shaking and rocking for maximal fluid ... 330 mm stainless steel or acrylic platform, it ... room operation. The platform angle is easily adjusted ... with action and rotation speed of platform is ...
...
Monoclonal Anti-Cystatin A tissue culture supernatant Solution containing 15 mM sodium azide human cystatin A ...
Biology Products: